Fennec Pharmaceuticals Reports 72% Increase in Q1 2026 Net Product Sales

Fennec Pharmaceuticals Inc. reported a significant increase in financial performance for the first quarter of 2026, with net product sales of $15.1 million, up from $8.8 million in the same period last year. This 72% increase is attributed to enhanced market penetration and access for its FDA-approved product, PEDMARK®, which is designed to reduce the risk of ototoxicity associated with cisplatin in pediatric patients. The company also achieved a net income of $201,000, a notable turnaround from a net loss of $1.2 million in the first quarter of 2025. The basic net income per share was reported at $0.01, compared to a loss of $0.04 per share in the prior year.

Operating expenses for the quarter totaled $15.2 million, an increase from $9.6 million in the previous year, primarily driven by a substantial rise in selling and marketing expenses, which surged to $11.4 million from $3.2 million. This increase reflects the company's strategic decision to expand its sales force and enhance coverage in the U.S. market. Research and development expenses decreased slightly to $0.5 million, while general and administrative expenses fell significantly by $2.7 million, largely due to reduced legal and professional fees as litigation activities concluded.

Fennec's balance sheet as of March 31, 2026, showed total assets of $71.8 million, a slight increase from $70.6 million at the end of 2025. Cash and cash equivalents rose to $40.2 million, up from $36.8 million, reflecting improved cash flow from operations. Current liabilities decreased to $9.6 million from $10.5 million, indicating better management of accrued liabilities. The company’s stockholders' equity increased to $37.7 million, up from $35.5 million, supported by the issuance of new shares and stock options.

In terms of strategic developments, Fennec entered into a licensing agreement with Norgine Pharma in March 2024, granting Norgine exclusive rights to commercialize PEDMARQSI® in Europe, Australia, and New Zealand. This agreement included an upfront payment of approximately $43 million and potential milestone payments totaling up to $230 million. The company also announced a settlement with Cipla regarding patent litigation, allowing Cipla to delay market entry of its generic product until September 1, 2033, thereby enhancing Fennec's market exclusivity for PEDMARK®.

Looking ahead, Fennec Pharmaceuticals remains optimistic about its growth trajectory, with plans to expand its market presence and continue enhancing the adoption of PEDMARK®. The company is also pursuing regulatory registration for PEDMARK® in Japan following positive results from an investigator-initiated trial. With a focus on increasing awareness of cisplatin-induced ototoxicity and the benefits of PEDMARK®, Fennec aims to solidify its position as a leader in this niche market.